These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 19199897)

  • 1. Intravitreal bevacizumab for diabetic retinopathy.
    Arevalo JF; Garcia-Amaris RA
    Curr Diabetes Rev; 2009 Feb; 5(1):39-46. PubMed ID: 19199897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal Bevacizumab (Avastin(®)) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture.
    Arevalo JF; Sanchez JG; Lasave AF; Wu L; Maia M; Bonafonte S; Brito M; Alezzandrini AA; Restrepo N; Berrocal MH; Saravia M; Farah ME; Fromow-Guerra J; Morales-Canton V;
    Curr Diabetes Rev; 2010 Sep; 6(5):313-22. PubMed ID: 20594160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy for diabetic macular edema.
    Al Rashaed S; Arevalo JF
    Middle East Afr J Ophthalmol; 2013; 20(4):315-20. PubMed ID: 24339681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of intravitreal bevacizumab on macular thickness: exploring serum and vitreous proangiogenic biomarkers in patients with diabetic macular edema.
    Malik TG; Ahmed SS; Gul R; Khalil M; Malik AA; Khan M
    Turk J Med Sci; 2018 Aug; 48(4):833-839. PubMed ID: 30119160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema.
    Faghihi H; Roohipoor R; Mohammadi SF; Hojat-Jalali K; Mirshahi A; Lashay A; Piri N; Faghihi Sh
    Eur J Ophthalmol; 2008; 18(6):941-8. PubMed ID: 18988166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study.
    Bonini-Filho M; Costa RA; Calucci D; Jorge R; Melo LA; Scott IU
    Am J Ophthalmol; 2009 Jun; 147(6):1022-30, 1030.e1-5. PubMed ID: 19327746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
    Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA
    Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current intravitreal pharmacologic therapies for diabetic macular edema.
    Colucciello M
    Postgrad Med; 2015 Aug; 127(6):640-53. PubMed ID: 26036708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
    Shimura M; Nakazawa T; Yasuda K; Shiono T; Iida T; Sakamoto T; Nishida K
    Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema.
    Chung EJ; Roh MI; Kwon OW; Koh HJ
    Retina; 2008; 28(7):957-63. PubMed ID: 18698297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
    Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
    Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema.
    Soliman W; Vinten M; Sander B; Soliman KA; Yehya S; Rahman MS; Larsen M
    Acta Ophthalmol; 2008 Jun; 86(4):365-71. PubMed ID: 18028237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema.
    Chen E; Hsu J; Park CH
    Ophthalmic Surg Lasers Imaging; 2009; 40(1):68-70. PubMed ID: 19205502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
    Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
    Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic macular edema.
    Lang GE
    Ophthalmologica; 2012; 227 Suppl 1():21-9. PubMed ID: 22517122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of intravitreal bevacizumab (Avastin) for short-term treatment of diabetic macular edema.
    Nagasawa T; Naito T; Matsushita S; Sato H; Katome T; Shiota H
    J Med Invest; 2009 Aug; 56(3-4):111-5. PubMed ID: 19763022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intravitreal bevacizumab followed by focal laser for diffuse diabetic macular edema of recent progression. A clinical case].
    Moreno-López M; Regueras A
    Arch Soc Esp Oftalmol; 2009 Apr; 84(4):209-12. PubMed ID: 19384761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
    Krick TW; Bressler NM
    Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.